PAINWeek 2012: Neuropathic Pain

Tapentadol extended-release tablets is efficacious in the management of moderate-to-severe chronic pain associated with diabetic peripheral neuropathy in adults, according study results presented at PAINWeek 2012.

When used in combination with pregabalin and gabapentin, lidocaine 5% patch is well tolerated and safe for postherpetic neuralgia (PHN), according to a presentation at PAINWeek 2012.

Lidocaine patch 5% is effective and well-tolerated if applied to the face, trunk, or extremities, according to the results of a study in patients with postherpetic neuralgia reported during PAINWeek 2012.

Patients with chronic neuropathic pain can be safely and effectively converted and maintained on hydromorphone extended-release, as shown in a study presented at PAINWeek 2012.

Charles E. Argoff, MD, from Albany (NY) Medical Center, discussed diabetic peripheral neuropathy, at PAINWeek 2012, including how to recognize and treat this often undiagnosed condition.

A study presented at PAINWeek 2012 reported that tapentadol extended-release (ER) was effective and well tolerated for managing chronic diabetic peripheral neuropathy.

A once-daily gastroretentive formulation of gabapentin, which for patients in the fed state lingers in the stomach for an estimated 8 hours, can be an efficacious option for postherpetic neuralgia, including a very elderly (age ≥75 years) population, as presented at PAINWeek 2012.

Hydromorphone extended-release (ER) demonstrated similar efficacy in treating neuropathic or non-neuropathic chronic low back pain (LBP), as presented at PAINWeek 2012.

At PAINWeek 2012, study data showed that tapentadol extended-release (ER) tablets formulated with a polyethylene oxide matrix produced tablets that were resistant to crushing or extraction, as reported by Joseph Pergolizzi, MD, of Naples Anesthesia and Pain Associates, Naples, FL.

At PAINWeek 2012, Wing Chow, PharmD, MPH, of Janssen Scientific Affairs, Raritan, NJ, and colleagues reported that the presence of prior antidepressant or anticonvulsant use is the most significant predictor of a patient receiving new medication for diabetic peripheral neuropathy (DPN).